– USA, NV – Zura Bio Limited (Nasdaq: ZURA), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Arnout Ploos van Amstel to its Board as an Independent Non-Executive Director, replacing Dr. Garry Neil who stepped down from the Board.
“I am pleased to extend a warm welcome to Arnout as our newest addition to the Board. With an impressive career spanning several decades, his expertise in strategy and business transformations brings a valuable dimension to our Board. His leadership will undoubtedly be a significant asset as we work towards creating sustained value for our company,” said CEO and Board member, Dr. Someit Sidhu.
About Arnout Ploos van Amstel
With a career spanning over three decades in the global biotech and pharmaceutical sector, Arnout Ploos van Amstel has built a successful track record in a wide variety of leadership positions. He consistently excelled in devising and implementing comprehensive strategies across the Development, Medical, and Commercial-Access domains. He currently works as a strategic consultant through his company Apaxcel Life Sciences GmbH, and he is a founder of MoonLake Immunotherapeutics AG, a biotech company dedicated to next-level therapies in inflammatory diseases. During his tenure as the leader of Novartis’ Global Business Unit Immunology/Dermatology, he achieved remarkable portfolio growth, notably with the success of COSENTYX (secukinumab), XOLAIR (omalizumab) for chronic spontaneous urticaria (CSU), and with the consistent growth of “orphan blockbuster” ILARIS (canakinumab). Mr. Ploos van Amstel’s experience includes leadership roles at Wyeth Pharmaceuticals and Novartis with executive positions in the United States, Canada, Greece, the Netherlands, and Switzerland.
“I am honored to join the Board of Directors at Zura Bio and enthusiastic about collaborating with this exceptionally skilled team that is dedicated to making a transformational impact on the lives of patients worldwide,” said Mr. Ploos van Amstel. “I look forward to contributing to the company’s ambition to accelerate innovation in the critical fields of inflammation and immunology.”
About Zura Bio
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (torudokimab) to demonstrate their efficacy, safety, and dosing convenience in immune and inflammatory disorders, including systemic sclerosis, hidradenitis suppurativa, and other novel indications with unmet needs.
SOURCE: https://zurabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
